Global Information
회사소개 | 문의 | 비교리스트

세계의 수두증 시장 기회 분석 및 산업 예측(2021-2030년) : 원인, 유형, 진단, 치료, 연령별

Hydrocephalus Market by Cause, Type, Diagnosis, Treatment, and Age : Global Opportunity Analysis and Industry Forecast, 2021--2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059621
페이지 정보 영문 280 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 수두증 시장 기회 분석 및 산업 예측(2021-2030년) : 원인, 유형, 진단, 치료, 연령별 Hydrocephalus Market by Cause, Type, Diagnosis, Treatment, and Age : Global Opportunity Analysis and Industry Forecast, 2021--2030
발행일 : 2021년 12월 페이지 정보 : 영문 280 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 수두증 시장 규모는 2020년 69억 750만 달러에서 예측기간에는 4.0%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 101억 7,860만 달러 규모로 성장할 것으로 예측됩니다.

수두증 환자 증가가 시장 성장의 원동력이 되고 있습니다. 수두증 관리를 위한 뇌신경외과 기기 및 부속품에 대한 높은 수요, 선천성 이상과 생활습관병에 의한 신경장애 증례 증가, 뇌 및 신경 손상 발생률 증가 또한 수두증 션트 수요를 높이고 있습니다. 한편, 감염증이나 기존 션트의 불편에 의한 심각한 데미지가 시장 성장을 크게 억제하고 있습니다. 유해한 합병증에는 불가역적인 뇌손상, 수막염, 심내막염, 외상성 천공, 삼첨판 역류, 심부전, 폐고혈압 등이 있습니다.

세계의 수두증(Hydrocephalus) 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모 추이와 예측, 원인·유형·진단·치료·연령·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
  • 주요 기업의 포지셔닝
  • 교통성 수두증 : 원인, 증상 및 치료
  • COVID-19 : 시장에 대한 영향

제4장 수두증 시장 : 원인별

  • 개요
  • 선천성 수두증
  • 후천성 수두증
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 수두증 시장 : 유형별

  • 개요
  • 주요 시장 동향과 성장 기회
  • 시장 규모와 예측 : 지역별
  • 시장 분석 : 국가별
  • 교통성 수두증
    • 정상압 수두증
    • 무강 수두증
  • 비교통성 수두증

제6장 수두증 시장 : 진단별

  • 개요
  • CT 스캔
  • MRI
  • 초음파
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제7장 수두증 시장 : 치료별

  • 개요
  • 외과적 션트 삽입
  • 뇌실막 절개술
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제8장 수두증 시장 : 연령별

  • 개요
  • 신생아 및 소아
  • 성인
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제9장 수두증 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측 : 원인별
    • 시장 규모와 예측 : 유형별
    • 시장 규모와 예측 : 진단별
    • 시장 규모와 예측 : 치료별
    • 시장 규모와 예측 : 연령별
    • 시장 규모와 예측 : 국가별

제10장 기업 개요

  • AESCULAP INC.(B. BRAUN COMPANY)
  • INTEGRA LIFE SCIENCES INC.
  • KARL STORZ SE AND CO. KG
  • MEDTRONIC PLC
  • NATUS MEDICAL INCORPORATED

제11장 기업 개요 : 서비스 기반

  • BOSTON CHILDREN'S HOSPITAL
  • ANADOLU MEDICAL CENTER.
  • HELIOS HOSPITAL
  • TEXAS CHILDREN'S HOSPITAL
  • CHILDREN'S NATIONAL HOSPITAL
LSH 22.03.10

LIST OF TABLES

LIST OF TABLE

  • TABLE 01.GLOBAL HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 02.CONGENITAL HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.FOR ACQUIRED HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 05.COMMUNICATING HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.COMMUNICATING HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 07.NON-COMMUNICATING HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 09.GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 (VOLUME UNITS)
  • TABLE 10.HYDROCEPHALUS MARKET FOR CT SCAN, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.HYDROCEPHALUS MARKET FOR MRI, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 14.HYDROCEPHALUS MARKET FOR SURGERY SHUNT INSERTION, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.GLOBAL HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 17.HYDROCEPHALUS MARKET FOR NEONATE AND PEDIATRICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 21.NORTH AMERICA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 23.NORTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 24.NORTH AMERICA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 25.NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 26.U.S. HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 27.U.S. HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 28.U.S. HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 29.U.S. HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 30.U.S. HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 31.CANADA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 32.CANADA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 33.CANADA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 34.CANADA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 35.CANADA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 36.MEXICO HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 37.MEXICO HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 38.MEXICO HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 39.MEXICO HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 40.MEXICO HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 41.EUROPE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 42.EUROPE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 43.EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 44.EUROPE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 45.EUROPE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 46.EUROPE HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 47.GERMANY HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 48.GERMANY HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 49.GERMANY HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 50.GERMANY HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 51.GERMANY HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 52.FRANCE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 53.FRANCE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 54.FRANCE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 55.FRANCE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 56.FRANCE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 57.UK HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 58.UK HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 59.UK HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 60.UK HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 61.UK HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 62.ITALY HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 63.ITALY HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 64.ITALY HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 65.ITALY HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 66.ITALY HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 67.SPAIN HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 68.SPAIN HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 69.SPAIN HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 70.SPAIN HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 71.SPAIN HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 72.REST OF EUROPE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 73.REST OF EUROPE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 74.REST OF EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 75.REST OF EUROPE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 76.REST OF EUROPE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 77.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 78.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 79.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 80.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 81.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 82.ASIA-PACIFIC HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 83.CHINA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 84.CHINA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 85.CHINA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 86.CHINA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 87.CHINA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 88.JAPAN HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 89.JAPAN HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 90.JAPAN HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 91.JAPAN HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 92.JAPAN HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 93.INDIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 94.INDIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 95.INDIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 96.INDIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 97.INDIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 98.AUSTRALIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 99.AUSTRALIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 100.AUSTRALIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 101.AUSTRALIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 102.AUSTRALIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 103.SOUTH KOREA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 104.SOUTH KOREA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 105.SOUTH KOREA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 106.SOUTH KOREA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 107.AUSTRALIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 108.REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 109.REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 110.REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 111.REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 112.REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 113.LAMEA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 114.LAMEA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 115.LAMEA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 116.LAMEA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 117.LAMEA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 118.LAMEA HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 119.BRAZIL HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 120.BRAZIL HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 121.BRAZIL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 122.BRAZIL HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 123.BRAZIL HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 124.SAUDI ARABIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 125.SAUDI ARABIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 126.SAUDI ARABIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 127.SAUDI ARABIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 128.SAUDI ARABIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 129.SOUTH AFRICA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 130.SOUTH AFRICA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 131.SOUTH AFRICA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 132.SOUTH AFRICA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 133.SOUTH AFRICA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 134.REST OF LAMEA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
  • TABLE 135.REST OF LAMEA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 136.BRAZIL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
  • TABLE 137.REST OF LAMEA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
  • TABLE 138.REST OF LAMEA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
  • TABLE 139.AESCULAP (B. BRAUN): COMPANY SNAPSHOT
  • TABLE 140.AESCULAP (B.BRAUN): OPERATING SEGMENTS
  • TABLE 141.AESCULAP (B.BRAUN): PRODUCT PORTFOLIO
  • TABLE 142.AESCULAP (B.BRAUN): KEY DEVELOPMENTS
  • TABLE 143.INTEGRA: COMPANY SNAPSHOT
  • TABLE 144.INTEGRA: OPERATING SEGMENTS
  • TABLE 145.INTEGRA: PRODUCT PORTFOLIO
  • TABLE 146.INTEGRA: KEY DEVELOPMENTS
  • TABLE 147.KARL STORZ: COMPANY SNAPSHOT
  • TABLE 148.KARL STORZ: OPERATING SEGMENTS:
  • TABLE 149.KARL STORZ: PRODUCT PORTFOLIO
  • TABLE 150.MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 151.MEDTRONIC: OPERATING SEGMENTS
  • TABLE 152.MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 153.NATUS MEDICAL: COMPANY SNAPSHOT
  • TABLE 154.NATUS MEDICAL: OPERATING SEGMENTS
  • TABLE 155.NATUS MEDICAL: PRODUCT PORTFOLIO
  • TABLE 156.BOSTON: HOSPITAL SNAPSHOT
  • TABLE 157.ANADOLU MEDICAL CENTER: HOSPITAL SNAPSHOT
  • TABLE 158.HELIOS: HOSPITAL SNAPSHOT
  • TABLE 159.TEXAS CHILDREN'S HOSPITAL: HOSPITAL SNAPSHOT
  • TABLE 160.CHILDREN'S NATIONAL HOSPITAL: HOSPITAL SNAPSHOT

LIST OF FIGURES

  • FIGURE 01.HYDROCEPHALUS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017-2020* (%)
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2020*
  • FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 10.MODERATE COMPETITIVE REIVALRY
  • FIGURE 11.DRIVERS, RESTRAINTS, AND OPPORTUNITY
  • FIGURE 12.TOP PLAYER POSITIONING, 2020
  • FIGURE 13.COMPARATIVE ANALYSIS OF CONGENITAL HYDROCEPHALUS MARKET, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 14.COMPARATIVE ANALYSIS OF ACQUIRED HYDROCEPHALUS MARKET, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 15.COMPARATIVE ANALYSIS OF COMMUNICATING HYDROCEPHALUS MARKET, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 16.NORMAL PRESSURE HYDROCEPHALUS, 2020-2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR NON-COMMUNICATING

HYDROCEPHALUS, BY COUNTRY, 2020 & 2030 ($MILLION)

  • FIGURE 18.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR CT SCAN, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 19.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR MRI, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 20.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY COUNTRY,

2020 & 2030 ($MILLION)

  • FIGURE 21.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR SURGERY SHUNT INSERTION,

BY COUNTRY, 2020 & 2030 ($MILLION)

  • FIGURE 22.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY COUNTRY,
  • 2020 & 2030 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR NEONATE AND PEDIATRICS,

BY COUNTRY, 2020 & 2030 ($MILLION)

  • FIGURE 24.COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR ADULTS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 25.B. BRAUN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.B. BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 27.B. BRAUN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 28.INTEGRA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.INTEGRA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.INTEGRA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 31.MEDTRONIC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 33.MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 34.NATUS MEDICAL: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.NATUS MEDICAL: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 36.NATUS MEDICAL: REVENUE SHARE, BY REGION, 2020 (%)

The global hydrocephalus market was valued at $6907.5 million in 2020 and is projected to reach $10178.6 million by 2030, registering a CAGR of 4.0% from 2021 to 2030.

Hydrocephalus is a chronic, neurological disorder caused by an abnormal accumulation of cerebrospinal fluid (CSF) within cavities of the brain called ventricles. This increase in volume results on elevated pressure within the cranium, which can cause irreversible damage to the brain tissue. The human body produces 500 ml of CSF on daily basis, with continuous replacement of the fluid as it is absorbed. In normal conditions, there is a subtle balance between the amount of fluid produced and the rate at which it is absorbed within the body. Hydrocephalus occurs when there is a disruption in this balance. Hydrocephalus can be treated in a variety of ways based on the aetiology of the disorder. But it is most commonly treated indirectly by implanting a medical device known as a "shunt" to divert the excess CSF away from the brain. A shunt, is a flexible tube, which is placed in the ventricular system of the brain that diverts the flow of CSF to another region of the body, most often the abdominal cavity, or heart, where it can be absorbed. Moreover, other treatment options for hydrocephalus include ventriculostomy and medications. One of the prominent factors responsible for the growth hydrocephalus market includes the increase in the number of hydrocephalic patients, which subsequently leads to the increase in the number of shunting procedures across the world. For instance, according to the hydrocephalus association, in 2021, over 36,000 shunt surgeries are performed each year (one every 15 minutes) and more than half of them represent emergencies.

Moreover, high demand for neurosurgery devices & accessories for hydrocephalus management and a rise in cases of neurological disorders, owing to congenital abnormalities and lifestyle diseases as well as a rise in incidences of brain and nerve injuries, boosts the demand for hydrocephalic shunts.

Furthermore, the key developmental strategies such as product approval, partnership, and launch of various novel hydrocephalic valves by key players are further projected to propel the growth of the market. For instance, in 2021, Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) breakthrough device designation for its ReFlow System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus.

Furthermore, in 2020, Aesculap, Inc., in partnership with the Christoph Miethke GmbH & Co. KG (MIETHKE), announced the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution. These strategies are certainly enhancing the company's footprints in the Hydrocephalus market, thereby contributing to the overall growth of the market.

However, serious damages caused by infections and malfunctions of existing shunts greatly limit the market growth. Some deleterious complications include irreversible brain injuries, meningitis, endocarditis, traumatic perforation, tricuspid regurgitation, heart failure, pulmonary hypertension, and others. For instance, according to the Hydrocephalus Association, approximately 50% of shunts in the pediatric population fail within two years of placement, requiring repeated neurological operations. On the contrary, advancements in shunt technology for reducing shunt complications are projected to create lucrative opportunities for market growth.

The hydrocephalus market is segmented on the basis of cause, type, diagnosis, treatment, age and region. On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. By type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy.

The age is categorized into Neonate & Pediatrics and Adults. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global hydrocephalus shunt market are Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc., Medtronic Plc. and Natus Medical Inc. Further, the service provider of hydrocephalus is Boston Children's Hospital, Anadolu Medical Center, Helios Hospital, Texas Children's Hospital, and Children's National Hospital.

Key benefits for stakeholders

The study provides an in-depth analysis of the global hydrocephalus market along with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.

A comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps understand the different types of hydrocephalus across the globe.

Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key market segments

By Cause

  • Congenital hydrocephalus
  • Acquired hydrocephalus

By type

  • Communicating hydrocephalus
  • Normal Pressure hydrocephalus
  • Ex-vacuo hydrocephalus
  • Non- Communicating hydrocephalus

By Diagnosis

  • CT Scan
  • MRI
  • Ultrasound

By Treatment

  • Surgery shunt insertion
  • Ventriculostomy

By AGE

  • Neonate & Pediatrics
  • Adults

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • List of key players profile and Service provider in the report
  • Aesculap Inc.
  • Integra Lifesciences
  • Karl Storz Se And Co. Kg
  • Medtronic Plc
  • Natus Medical Inc.

By Service Provider

  • Boston Children's Hospital
  • Anadolu Medical Center
  • Helios Hospital
  • Texas Children's Hospital
  • Children's National Hospital

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profile and Service provider in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Growth in prevalence of hydrocephalus
      • 3.4.1.2.Surge in adoption of hydrocephalus shunt
      • 3.4.1.3.Increase in incidences of neurological disorders
    • 3.4.2.Restraint
      • 3.4.2.1.Shunt malfunction and related infections
    • 3.4.3.Opportunity
      • 3.4.3.1.Advancements in technology in the healthcare sector
  • 3.5.Top player positioning
  • 3.6.Communicating hydrocephalus: Causes, Symptoms, and Treatments
  • 3.7.COVID-19 Impact on the market

CHAPTER 4:HYDROCEPHALUS MARKET, BY CAUSE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Congenital Hydrocephalus
    • 4.2.1.Market size and forecast, by region
    • 4.2.2.Market share analysis, by country
  • 4.3.Acquired hydrocephalus
    • 4.3.1.Market size and forecast, by region
    • 4.3.2.Market analysis, by country

CHAPTER 5:HYDROCEPHALUS MARKET, BY TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Communicating hydrocephalus
    • 5.2.1.Key market trends and growth opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
    • 5.2.4.Market size and forecast, by type
      • 5.2.4.1.Normal pressure hydrocephalus
      • 5.2.4.1.1.Market size and forecast
      • 5.2.4.2.Ex-Vacuo hydrocephalus
      • 5.2.4.2.1.Market size and forecast
  • 5.3.Non-communicating hydrocephalus
    • 5.3.1.Key market trends and growth opportunities
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country

CHAPTER 6:HYDROCEPHALUS MARKET, BY DIAGNOSIS

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.CT Scan
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market share analysis, by country
  • 6.3.MRI
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Ultrasound
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:HYDROCEPHALUS MARKET, BY TREATMENT

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Surgery shunt insertion
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market share analysis, by country
  • 7.3.Ventriculostomy
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market analysis, by country

CHAPTER 8:HYDROCEPHALUS MARKET, BY AGE

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.Neonate and Pediatrics
    • 8.2.1.Market size and forecast, by region
    • 8.2.2.Market share analysis, by country
  • 8.3.Adults
    • 8.3.1.Market size and forecast, by region
    • 8.3.2.Market analysis, by country

CHAPTER 9:HYDROCEPHALUS MARKET, BY REGION

  • 9.1.Overview
    • 9.1.1.Market size and forecast
  • 9.2.North America
    • 9.2.1.Key market trends, growth factors, and opportunities
    • 9.2.2.North America market size and forecast, by cause
    • 9.2.3.North America market size and forecast, by type
    • 9.2.4.North America market size and forecast, by diagnosis
    • 9.2.5.North America market size and forecast, by treatment
    • 9.2.6.North America market size and forecast, by age
    • 9.2.7.Market size and forecast, by country
      • 9.2.7.1.U.S.
      • 9.2.7.1.1.U.S. Hydrocephalus Market, by cause
      • 9.2.7.1.2.U.S. Hydrocephalus Market, by type
      • 9.2.7.1.3.U.S. Hydrocephalus Market, by diagnosis
      • 9.2.7.1.4.U.S. Hydrocephalus Market, by treatment
      • 9.2.7.1.5.U.S. Hydrocephalus Market, by age
      • 9.2.7.2.Canada
      • 9.2.7.2.1.Canada Hydrocephalus Market, by cause
      • 9.2.7.2.2.Canada Hydrocephalus Market, by type
      • 9.2.7.2.3.Canada Hydrocephalus Market, by diagnosis
      • 9.2.7.2.4.Canada Hydrocephalus Market, by treatment
      • 9.2.7.2.5.Canada Hydrocephalus Market, by age
      • 9.2.7.3.Mexico
      • 9.2.7.3.1.Mexico Hydrocephalus Market, by cause
      • 9.2.7.3.2.Mexico Hydrocephalus Market, by type
      • 9.2.7.3.3.Mexico Hydrocephalus Market, by diagnosis
      • 9.2.7.3.4.Mexico Hydrocephalus Market, by treatment
      • 9.2.7.3.5.Mexico Hydrocephalus Market, by age
  • 9.3.Europe
    • 9.3.1.Key market trends, growth factors, and opportunities
    • 9.3.2.Europe market size and forecast, by cause
    • 9.3.3.Europe market size and forecast, by type
    • 9.3.4.Europe market size and forecast, by diagnosis
    • 9.3.5.Europe market size and forecast, by treatment
    • 9.3.6.Europe market size and forecast, by age
    • 9.3.7.Market size and forecast, by country
      • 9.3.7.1.Germany
      • 9.3.7.1.1.Germany Hydrocephalus Market, by cause
      • 9.3.7.1.2.Germany Hydrocephalus Market, by type
      • 9.3.7.1.3.Germany Hydrocephalus Market, by diagnosis
      • 9.3.7.1.4.Germany Hydrocephalus Market, by treatment
      • 9.3.7.1.5.Germany Hydrocephalus Market, by age
      • 9.3.7.2.France
      • 9.3.7.2.1.France Hydrocephalus Market, by cause
      • 9.3.7.2.2.France Hydrocephalus Market, by type
      • 9.3.7.2.3.France Hydrocephalus Market, by diagnosis
      • 9.3.7.2.4.France Hydrocephalus Market, by treatment
      • 9.3.7.2.5.France Hydrocephalus Market, by age
      • 9.3.7.3.UK
      • 9.3.7.3.1.UK Hydrocephalus Market, by cause
      • 9.3.7.3.2.UK Hydrocephalus Market, by type
      • 9.3.7.3.3.UK Hydrocephalus Market, by diagnosis
      • 9.3.7.3.4.UK Hydrocephalus Market, by treatment
      • 9.3.7.3.5.UK Hydrocephalus Market, by age
      • 9.3.7.4.Italy
      • 9.3.7.4.1.Italy Hydrocephalus Market, by cause
      • 9.3.7.4.2.Italy Hydrocephalus Market, by type
      • 9.3.7.4.3.Italy Hydrocephalus Market, by diagnosis
      • 9.3.7.4.4.Italy Hydrocephalus Market, by treatment
      • 9.3.7.4.5.Italy Hydrocephalus Market, by age
      • 9.3.7.5.Spain
      • 9.3.7.5.1.Spain Hydrocephalus Market, by cause
      • 9.3.7.5.2.Spain Hydrocephalus Market, by type
      • 9.3.7.5.3.Spain Hydrocephalus Market, by diagnosis
      • 9.3.7.5.4.Spain Hydrocephalus Market, by treatment
      • 9.3.7.5.5.Spain Hydrocephalus Market, by age
      • 9.3.7.6.Rest of Europe
      • 9.3.7.6.1.Rest of Europe Hydrocephalus Market, by cause
      • 9.3.7.6.2.Rest of Europe Hydrocephalus Market, by type
      • 9.3.7.6.3.Rest of Europe Hydrocephalus Market, by diagnosis
      • 9.3.7.6.4.Rest of Europe Hydrocephalus Market, by treatment
      • 9.3.7.6.5.Rest of Europe Hydrocephalus Market, by age
  • 9.4.Asia-Pacific
    • 9.4.1.Key market trends, growth factors, and opportunities
    • 9.4.2.Asia-Pacific market size and forecast, by cause
    • 9.4.3.Asia-Pacific market size and forecast, by type
    • 9.4.4.Asia-Pacific market size and forecast, by diagnosis
    • 9.4.5.Asia-Pacific market size and forecast, by treatment
    • 9.4.6.Asia-Pacific market size and forecast, by age
    • 9.4.7.Market size and forecast, by country
      • 9.4.7.1.China
      • 9.4.7.1.1.China Hydrocephalus Market, by Cause
      • 9.4.7.1.2.China Hydrocephalus Market, by type
      • 9.4.7.1.3.China Hydrocephalus Market, by diagnosis
      • 9.4.7.1.4.China Hydrocephalus Market, by treatment
      • 9.4.7.1.5.China Hydrocephalus Market, by age
      • 9.4.7.2.Japan
      • 9.4.7.2.1.Japan Hydrocephalus Market, by cause
      • 9.4.7.2.2.Japan Hydrocephalus Market, by type
      • 9.4.7.2.3.Japan Hydrocephalus Market, by diagnosis
      • 9.4.7.2.4.Japan Hydrocephalus Market, by treatment
      • 9.4.7.2.5.Japan Hydrocephalus Market, by age
      • 9.4.7.3.India
      • 9.4.7.3.1.India Hydrocephalus Market, by cause
      • 9.4.7.3.2.India Hydrocephalus Market, by type
      • 9.4.7.3.3.India Hydrocephalus Market, by diagnosis
      • 9.4.7.3.4.India Hydrocephalus Market, by treatment
      • 9.4.7.3.5.India Hydrocephalus Market, by age
      • 9.4.7.4.Australia
      • 9.4.7.4.1.Australia Hydrocephalus Market, by cause
      • 9.4.7.4.2.Australia Hydrocephalus Market, by type
      • 9.4.7.4.3.Australia Hydrocephalus Market, by diagnosis
      • 9.4.7.4.4.Australia Hydrocephalus Market, by treatment
      • 9.4.7.4.5.Australia Hydrocephalus Market, by age
      • 9.4.7.5.South Korea
      • 9.4.7.5.1.South Korea Hydrocephalus Market, by cause
      • 9.4.7.5.2.South Korea Hydrocephalus Market, by type
      • 9.4.7.5.3.South Korea Hydrocephalus Market, by diagnosis
      • 9.4.7.5.4.South Korea Hydrocephalus Market, by treatment
      • 9.4.7.5.5.South Korea Hydrocephalus Market, by age
      • 9.4.7.6.Rest of Asia-Pacific
      • 9.4.7.6.1.Rest of Asia-Pacific Hydrocephalus Market, by cause
      • 9.4.7.6.2.Rest of Asia-Pacific Hydrocephalus Market, by type
      • 9.4.7.6.3.Rest of Asia-Pacific Hydrocephalus Market, by diagnosis
      • 9.4.7.6.4.Rest of Asia-Pacific Hydrocephalus Market, by treatment
      • 9.4.7.6.5.Rest of Asia-Pacific Hydrocephalus Market, by age
  • 9.5.LAMEA
    • 9.5.1.Key market trends, growth factors, and opportunities
    • 9.5.2.LAMEA market size and forecast, by cause
    • 9.5.3.LAMEA market size and forecast, by type
    • 9.5.4.LAMEA market size and forecast, by diagnosis
    • 9.5.5.LAMEA market size and forecast, by treatment
    • 9.5.6.LAMEA market size and forecast, by age
    • 9.5.7.Market size and forecast, by country
      • 9.5.7.1.Brazil
      • 9.5.7.1.1.Brazil Hydrocephalus Market, by cause
      • 9.5.7.1.2.Brazil Hydrocephalus Market, by type
      • 9.5.7.1.3.Brazil Hydrocephalus Market, by diagnosis
      • 9.5.7.1.4.Brazil Hydrocephalus Market, by treatment
      • 9.5.7.1.5.Brazil Hydrocephalus Market, by age
      • 9.5.7.2.Saudi Arabia
      • 9.5.7.2.1.Saudi Arabia Hydrocephalus Market, by cause
      • 9.5.7.2.2.Saudi Arabia Hydrocephalus Market, by type
      • 9.5.7.2.3.Saudi Arabia Hydrocephalus Market, by diagnosis
      • 9.5.7.2.4.Saudi Arabia Hydrocephalus Market, by treatment
      • 9.5.7.2.5.Saudi Arabia Hydrocephalus Market, by age
      • 9.5.7.3.South Africa
      • 9.5.7.3.1.South Africa Hydrocephalus Market, by cause
      • 9.5.7.3.2.South Africa Hydrocephalus Market, by type
      • 9.5.7.3.3.South Africa Hydrocephalus Market, by diagnosis
      • 9.5.7.3.4.South Africa Hydrocephalus Market, by treatment
      • 9.5.7.3.5.South Africa Hydrocephalus Market, by age
      • 9.5.7.4.Rest of LAMEA
      • 9.5.7.4.1.Rest of LAMEA Hydrocephalus Market, by cause
      • 9.5.7.4.2.Rest of LAMEA Hydrocephalus Market, by type
      • 9.5.7.4.3.Rest of LAMEA Hydrocephalus Market, by diagnosis
      • 9.5.7.4.4.Rest of LAMEA Hydrocephalus Market, by treatment
      • 9.5.7.4.5.Rest of LAMEA Hydrocephalus Market, by age

CHAPTER 10:COMPANY PROFILES

  • 10.1.AESCULAP INC. (B. BRAUN COMPANY)
    • 10.1.1.Company overview
    • 10.1.2.Operating business segments
    • 10.1.3.Product portfolio
    • 10.1.4.Business performance
    • 10.1.5.Key strategic moves and developments
  • 10.2.INTEGRA LIFE SCIENCES INC.
    • 10.2.1.Company overview
    • 10.2.2.Operating business segments
    • 10.2.3.Product portfolio
    • 10.2.4.Business performance
    • 10.2.5.Key strategic moves and developments
  • 10.3.KARL STORZ SE AND CO. KG
    • 10.3.1.Company overview
    • 10.3.2.Operating business segments
    • 10.3.3.Product portfolio
  • 10.4.MEDTRONIC PLC
    • 10.4.1.Company overview
    • 10.4.2.Operating business segments
    • 10.4.3.Product portfolio
    • 10.4.4.Business performance
  • 10.5.NATUS MEDICAL INCORPORATED
    • 10.5.1.Company overview
    • 10.5.2.Company snapshot
    • 10.5.3.Operating business segments
    • 10.5.4.Product portfolio
    • 10.5.5.Business performance

CHAPTER 11:COMPANY PROFILES: SERVICE BASED

  • 11.1.BOSTON CHILDREN'S HOSPITAL
    • 11.1.1.Hospital overview
    • 11.1.2.Hospital snapshot
  • 11.2.ANADOLU MEDICAL CENTER.
    • 11.2.1.Hospital overview
    • 11.2.2.Hospital snapshot
  • 11.3.HELIOS HOSPITAL
    • 11.3.1.Hospital overview
    • 11.3.2.Hospital snapshot
  • 11.4.TEXAS CHILDREN'S HOSPITAL
    • 11.4.1.Hospital overview
    • 11.4.2.Hospital snapshot
  • 11.5.CHILDREN'S NATIONAL HOSPITAL
    • 11.5.1.Hospital overview
    • 11.5.2.Hospital snapshot
Back to Top
전화 문의
F A Q